Current trends in development of HDAC-based chemotherapeutics.

导出 LinkOut

翻译打印收藏纠错

作者： Narges,Cheshmazar ^[1] ; Maryam,Hamzeh-Mivehroud ^[2] ; Hojjatollah,Nozad Charoudeh ^[3] ; Salar,Hemmati ^[4] ; Jelena,Melesina ^[5] ; Siavoush,Dastmalchi ^[6]

作者单位： Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Medicinal Chemistry, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. ^[1] Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Medicinal Chemistry, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. ^[2] Anatomical Sciences Department, Faculty of Medicine, Tabriz University of Medical, Tabriz, Iran. ^[3] Drug applied research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ^[4] Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle, Germany. ^[5] Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Medicinal Chemistry, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; Faculty of Pharmacy, Near East University, POBOX:99138, Nicosia, North Cyprus, Mersin 10, Turkey. Electronic address: dastmalchi.s@tbzmed.ac.ir. ^[6]

关键词 Cancer Drug design HDAC degraders Histone deacetylase inhibitor Isoform-selective Multitargeted drugs

主题词药物设计(Drug Design);药物发现(Drug Discovery);组蛋白脱乙酰基酶抑制剂(Histone Deacetylase Inhibitors);组蛋白脱乙酰基酶类(Histone Deacetylases);蛋白质亚型(Protein Isoforms)

DOI 10.1016/j.lfs.2022.120946

PMID 36096240

发布时间 2022-10-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交